This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Quest Diagnostics (DGX) Partners to Offer New Testing Service
by Zacks Equity Research
Quest Diagnostics' (DGX) latest test indicates how different genes and their variants affect how a person reacts to drugs.
Here's Why You Should Buy Boston Scientific (BSX) Stock
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) strong improvement in organic sales, indicating a solid rebound in the legacy business.
Are You Looking for a Top Momentum Pick? Why Conmed (CNMD) is a Great Choice
by Zacks Equity Research
Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
IDEXX (IDXX) Stock Up 18.4% YTD: Will the Rally Continue?
by Zacks Equity Research
The continued solid demand for veterinary services and benefits from strong execution poise IDEXX (IDXX) well for future growth.
Hologic (HOLX) Gains From Core Businesses' Growth, Innovation
by Zacks Equity Research
Hologic's (HOLX) GYN Surgical business grows organically as the company registers procedural volumes return and acceleration from new business lines.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
CONMED (CNMD) Stock Hits 52-Week High: Will It Continue?
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism in investors due to its broad product spectrum.
IDEXX (IDXX) Launches First Veterinary Diagnostic Test
by Zacks Equity Research
IDEXX's (IDXX) Cystatin B Test can help veterinary professionals to spot kidney damage before it affects kidney function, which may result in better patient outcomes.
Here's Why You Should Invest in Hologic (HOLX) Stock Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) on continued strength in GYN Surgical and Breast Health businesses.
Masimo (MASI) Inks Deals for Patient Monitoring Technologies
by Zacks Equity Research
Masimo's (MASI) advanced monitoring technologies and solutions attract new customers looking for better patient care, using remote and centralized surveillance, and seamless data transfer to EMRs.
NextGen (NXGN) Expands Partnership With Large Urology Group
by Zacks Equity Research
NextGen's (NXGN) cloud-based healthcare technology solution, Enterprise EHR, is selected by Associated Urologists of North Carolina to create an integrated platform, especially for urology-specific workflows.
Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Cooper Companies (COO) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cooper Companies' (COO) second-quarter fiscal 2023 revenues reflect a solid segmental performance despite a year-over-year decline in earnings.
PDCO or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Here's Why You Should Retain Veradigm (MDRX) Stock for Now
by Zacks Equity Research
Veradigm (MDRX) continues to hold on to investors' interests owing to its strategic alliances.
Why You Should Buy The Cooper Companies (COO) Stock Now
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
CONMED (CNMD) Beats on Q1 Earnings, Ups '23 EPS View
by Zacks Equity Research
CONMED's (CNMD) adjusted first-quarter sales and earnings recover from the disruption in the fourth quarter due to implementation of a new warehouse management system.
Conmed (CNMD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 10% and 10.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q1 Earnings Due on Apr 26: MMSI, CNMD & More
by Indrajit Bandyopadhyay
Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MMSI, CNMD, NVRO and ARAY are likely to have performed this time.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD), owing to its broad product spectrum.
CONMED (CNMD) Down on Q4 Earnings Miss, New System Hurts Sales
by Zacks Equity Research
CONMED's (CNMD) adjusted fourth-quarter sales and earnings reflect disruption due to implementation of a new warehouse management system.
Conmed (CNMD) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of -54.84% and 18.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?